Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature
Open Access
- 1 January 2020
- journal article
- review article
- Published by Informa UK Limited in Vascular Health and Risk Management
- Vol. 16, 111-123
- https://doi.org/10.2147/VHRM.S210561
Abstract
Background: Landiolol hydrochloride, a highly cardio-selective beta-1 blocker with an ultra-short-acting half-life of 4 minutes, was originally approved by Japan for treatment of intraoperative tachyarrhythmias. This review aims to provide an integrated overview of the current state of knowledge of landiolol hydrochloride in the management of arrhythmia in critical settings. Methods: We searched MEDLINE, EMBASE, and the Cochrane Library to retrieve relevant articles with a total of 65 records identified. Results: The high beta 1 selectivity (beta 1/(beta 2 ratio of 255:1) of landiolol causes a more rapid heart rate (HR) decrease compared to esmolol while avoiding decreases in mean arterial blood pressure. Recently, it has been found useful in left ventricular dysfunction patients and fatal arrhythmia requiring emergency treatment. Recent random clinical trials (RCT) have revealed therapeutic and prophylactic effects on arrhythmia, and very low-dose landiolol might be effective for preventing postoperative atrial fibrillation (POAF) and sinus tachycardia. Likewise, landiolol is an optimal choice for perioperative tachycardia treatment during cardiac surgery. The high beta 1 selectivity of landiolol is useful in heart failure patients as a first-line therapy for tachycardia and arrhythmia as it avoids the typical depression of cardiac function seen in other beta-blockers. Application in cardiac injury after percutaneous coronary intervention (PCI), protection for vital organs (lung, kidney, etc.) during sepsis, and stabilizing hemodynamics in pediatric patients are becoming the new frontier of landiolol use. Conclusion: Landiolol is useful as a first-line therapy for the prevention of POAF after cardiac/non-cardiac surgery, fatal arrhythmias in heart failure patients and during PCI. Moreover, the potential therapeutic effect of landiolol for sepsis in pediatric patients is currently being explored. As positive RCT results continue to be published, new clinical uses and further clinical studies in various settings by cardiologists, intensivists and pediatric cardiologists are being conducted.Keywords
This publication has 85 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics, and Safety of Landiolol Hydrochloride in Healthy Chinese SubjectsDrug Research, 2013
- Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β1-Blocker, on Supraventricular Tachyarrhythmias in Postoperative PatientsClinical Drug Investigation, 2013
- Characteristic interactivity of landiolol, an ultra-short-acting highly selective β1-blocker, with biomimetic membranes: Comparisons with β1-selective esmolol and non-selective propranolol and alprenololFrontiers in Pharmacology, 2013
- Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular DysfunctionCirculation Journal, 2013
- Landiolol, an Ultra-Short-Acting β1-Blocker, More Effectively Terminates Atrial Fibrillation Than Diltiazem After Open Heart SurgeryCirculation Journal, 2012
- Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trialThe Journal of Thoracic and Cardiovascular Surgery, 2011
- Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) StudyCirculation, 2009
- Actual incidence of global left ventricular hypokinesia in adult septic shockCritical Care Medicine, 2008
- Studies on the Metabolic Fate of Ultra Short Acting .BETA.1 Blocker ONO-1101. (3). Metabolism and Protein Binding.Drug Metabolism and Pharmacokinetics, 1997
- Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.CHEMICAL & PHARMACEUTICAL BULLETIN, 1992